Company Overview
Actinium Pharmaceuticals, Inc. is a biotechnology enterprise focused on developing antibody radiation conjugates and other targeted radiotherapies designed to improve clinical outcomes for patients who have exhausted existing oncology therapies. The company currently advances two clinical stage product candidates, specifically Actimab-A, intended for the treatment of patients suffering from myeloid malignancies. Operating within the broader Healthcare sector and the specialized Biotechnology industry, the firm targets a niche area of oncology where traditional treatment options may have failed, positioning itself to address unmet medical needs in radiation therapy. In terms of scale, the company holds a market capitalization of $32.13M and generates an annual revenue of $90,000, supported by a workforce of 25 employees. These financial dimensions indicate that Actinium is a small-cap entity with limited revenue generation relative to its market valuation, a common characteristic for pre-revenue or early-stage biotechnology firms that prioritize research and development expenditures over immediate profit generation.
Financial Health
The financial statements for Actinium Pharmaceuticals, Inc. reveal a revenue of $90,000 over the trailing twelve months, accompanied by a net income of $-34,599,000 and an EBITDA of $-37,123,000. The substantial gap between the minimal revenue of $90,000 and the significant net loss of nearly $35 million highlights an extremely aggressive cost structure driven by the heavy research and development expenses inherent in advancing clinical stage product candidates. The company reported a free cash flow of $-13,220,250, which indicates that current operations are consuming cash reserves rather than generating liquidity, a typical scenario for biotech companies in the development phase. Despite the negative operating cash flow, the balance sheet holds $53.39M in cash against $1.14M in debt, suggesting a conservative leverage position where liquid assets vastly exceed obligations. The debt-to-equity ratio stands at 8.29, while the current ratio is reported at 7.96, indicating a strong short-term liquidity position despite the lack of profitability. The margins further reflect this developmental stage, with a gross margin of 100.0%, an operating margin of -6324.4%, and a profit margin of 0.0%. Return on Equity is -133.1% and Return on Assets is -33.8%, metrics that reveal management is currently sacrificing returns on capital to fund the long-term development of its therapeutic pipeline.
Valuation Assessment
Valuation metrics for Actinium Pharmaceuticals, Inc. present a complex picture due to the company's lack of earnings, with a trailing P/E ratio of N/A and a forward P/E of -1.30. The negative forward P/E implies that the market is pricing in future earnings expectations that have not yet materialized, as the company has not generated positive trailing earnings to support a standard trailing P/E calculation. The price-to-book ratio is 2.33, suggesting that the market values the company at a premium over its net asset book value, likely reflecting the potential value of its intellectual property and clinical pipeline. Alternative valuation measures such as the price-to-sales ratio of 357.02 and an EV/EBITDA of 0.54 indicate that investors are willing to pay a significant multiple to the company's sales despite the negligible revenue base. The stock has traded between a 52-week low of $1.01 and a 52-week high of $2.41, meaning the current price sits at a level that reflects high volatility typical of small-cap biotech stocks. The beta value of -0.30 indicates a price movement that is negatively correlated with the broader market, suggesting the stock may move inversely to general market trends during periods of volatility.
Growth & Income
Regarding growth metrics, the revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, reflecting the company's current stage of development where historical growth rates are not yet established. Since the company is not yet profitable, there are no earnings to grow at a faster or slower rate than revenue, as the focus remains entirely on capitalizing on future clinical successes rather than current operational expansion. Actinium does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which is consistent with its strategy of reinvesting all available resources into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current income distribution and undefined historical growth rates, relying entirely on the potential future approval and commercialization of its product candidates to drive value creation.